(UroToday.com) In this session, Dr. Ian Davis reviewed the evidence for “triplet therapy” comprising ADT plus docetaxel plus additional systemic therapy in metastatic hormone sensitive prostate cancer (mHSPC). He began with a high-level summary of five clinical trials that included patients treated with triplet therapy: TITAN, ARCHES, ENZAMET, PEACE-1, AND STAMPEDE M0. He noted key factors that are important to consider when comparing results across these trials, including different patient populations, endpoints, duration of follow-up, and whether docetaxel was given sequentially or concurrently. He then reviewed each trial individually.